User:Mr. Ibrahem/Remimazolam

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Remimazolam
Clinical data
Trade namesByfavo
Other namesRemimazolam besylate, CNS-7056[1]
AHFS/Drugs.comMonograph
License data
Routes of
administration		Intravenous
Drug classBenzodiazepine[2]
Legal status
Legal status
Pharmacokinetic data
Duration of action10 min[4]
Identifiers
  • methyl 3-[(4S)-8-bromo-1-methyl-6-(pyridin-2-yl)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate
Chemical and physical data
FormulaC21H19BrN4O2
Molar mass439.313 g·mol−1
3D model (JSmol)
  • COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21
  • InChI=1S/C21H19BrN4O2/c1-13-12-24-21-17(7-9-19(27)28-2)25-20(16-5-3-4-10-23-16)15-11-14(22)6-8-18(15)26(13)21/h3-6,8,10-12,17H,7,9H2,1-2H3/t17-/m0/s1 ☒N
  • Key:CYHWMBVXXDIZNZ-KRWDZBQOSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Remimazolam, sold under the brand name Byfavo, is a medication used for procedural sedation.[3] Specifically it is used in adults for procedures lasting less than 30 minutes.[3] It is given by injection into a vein.[3] While onset of effects is similar, the duration is shorter than midazolam.[5][6]

Common side effects include low blood pressure, high blood pressure, and low oxygen.[3] Other side effects may include abuse and allergic reactions.[3] Effectiveness is not altered in kidney problems, though lower doses may be used in those with liver problems.[3][7] Effects can be revered with flumazenil.[4] It is a benzodiazepine and works by attaching to gamma-amino butyric acid (GABA) receptors.[2]

Remimazolam was approved for medical use in the United States in 2020 and Europe in 2021.[3][2] In the United States a vial of 20 mg costs about 42 USD as of 2022.[8]

References[edit]

  1. ^ Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, et al. (2007). "CNS 7056: a novel ultra-short-acting Benzodiazepine". Anesthesiology. 107 (1): 60–6. doi:10.1097/01.anes.0000267503.85085.c0. PMID 17585216. S2CID 19504961.
  2. ^ a b c d "Byfavo EPAR". European Medicines Agency (EMA). 9 December 2020. Archived from the original on 21 April 2021. Retrieved 20 April 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. ^ a b c d e f g h i j "Byfavo- remimazolam besylate injection, powder, lyophilized, for solution". DailyMed. 20 July 2020. Archived from the original on 22 October 2022. Retrieved 25 February 2021.
  4. ^ a b Kaye, Alan David (5 June 2017). Pharmacology, An Issue of Anesthesiology Clinics. Elsevier Health Sciences. p. e101. ISBN 978-0-323-52998-3. Archived from the original on 12 November 2022. Retrieved 3 November 2022.
  5. ^ Noor, N; Legendre, R; Cloutet, A; Chitneni, A; Varrassi, G; Kaye, AD (2021). "A comprehensive review of remimazolam for sedation". Health psychology research. 9 (1): 24514. doi:10.52965/001c.24514. PMID 34746482.
  6. ^ Goudra, BG; Singh, PM (July 2014). "Remimazolam: The future of its sedative potential". Saudi journal of anaesthesia. 8 (3): 388–91. doi:10.4103/1658-354X.136627. PMID 25191193.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  7. ^ "Remimazolam Monograph for Professionals". Drugs.com. Retrieved 3 November 2022.
  8. ^ "Byfavo Prices, Coupons, Copay & Patient Assistance". Drugs.com. Archived from the original on 29 May 2022. Retrieved 3 November 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Remimazolam&oldid=1212350427"